{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:14:48Z","timestamp":1786990488656,"version":"build-2736575974"},"reference-count":29,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P50 CA247749"],"award-info":[{"award-number":["P50 CA247749"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017050","name":"Cycle for Survival","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","award":["P50 CA247749"],"award-info":[{"award-number":["P50 CA247749"]}],"id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.ijgc.2024.100005","type":"journal-article","created":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T09:44:51Z","timestamp":1736070291000},"page":"100005","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Basket study of oral progesterone antagonist onapristone extended-release in combination with anastrozole in progesterone receptor-positive recurrent adult-type granulosa cell tumor of the ovary"],"prefix":"10.1016","volume":"35","author":[{"given":"Lindsey","family":"Finch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2170-9632","authenticated-orcid":false,"given":"Sarah","family":"Andres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexia","family":"Iasonos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Girshman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi","family":"Chhetri-Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3944-6803","authenticated-orcid":false,"given":"Hunter","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier","family":"Selenica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dasom","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roisin E.","family":"O\u2019Cearbhaill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chrisann","family":"Kyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire F.","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicky","family":"Makker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis S.","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Sonoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Aghajanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"Weigelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel N.","family":"Grisham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ijgc.2024.100005_bib1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ygyno.2019.01.016","article-title":"The association between progesterone receptor expression and survival in women with adult granulosa cell tumors","volume":"153","author":"Puechl","year":"2019","journal-title":"Gynecol Oncol"},{"issue":"20","key":"10.1016\/j.ijgc.2024.100005_bib2","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1200\/JCO.2007.11.1005","article-title":"Management of ovarian stromal cell tumors","volume":"25","author":"Colombo","year":"2007","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ijgc.2024.100005_bib3","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw134","article-title":"Molecularly defined adult granulosa cell tumor of the ovary: the clinical phenotype","volume":"108","author":"McConechy","year":"2016","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.ijgc.2024.100005_bib4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13048-020-00619-6","article-title":"Characteristics and treatment results of recurrence in adult-type granulosa cell tumor of ovary","volume":"13","author":"Zhao","year":"2020","journal-title":"J Ovarian Res"},{"issue":"1","key":"10.1016\/j.ijgc.2024.100005_bib5","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ygyno.2013.04.047","article-title":"Recurrent granulosa cell tumors (GCTs) of the ovary: a MITO-9 retrospective study","volume":"130","author":"Mangili","year":"2013","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.ijgc.2024.100005_bib6","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1200\/JCO.2003.10.019","article-title":"Granulosa cell tumor of the ovary","volume":"21","author":"Schumer","year":"2003","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ijgc.2024.100005_bib7","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/pgp.0b013e31805c0d99","article-title":"Estrogen receptor alpha and progesterone receptor expression in ovarian adult granulosa cell tumors and Sertoli-Leydig cell tumors","volume":"26","author":"Farinola","year":"2007","journal-title":"Int J Gynecol Pathol"},{"issue":"1","key":"10.1016\/j.ijgc.2024.100005_bib8","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00261-007-9197-1","article-title":"Recurrent ovarian granulosa cell tumors: clinical and imaging features","volume":"33","author":"Rha","year":"2008","journal-title":"Abdom Imaging"},{"issue":"1","key":"10.1016\/j.ijgc.2024.100005_bib9","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/j.1447-0756.2011.01698.x","article-title":"Aromatase inhibitors in the treatment of recurrent ovarian granulosa cell tumors: brief report and review of the literature","volume":"38","author":"AlHilli","year":"2012","journal-title":"J Obstet Gynaecol Res"},{"issue":"1","key":"10.1016\/j.ijgc.2024.100005_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ctrv.2007.08.007","article-title":"Granulosa cell tumor of the ovary","volume":"34","author":"Pectasides","year":"2008","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"10.1016\/j.ijgc.2024.100005_bib11","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.bpobgyn.2007.08.003","article-title":"Hormonal therapies and gynaecological cancers","volume":"22","author":"Garrett","year":"2008","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"12","key":"10.1016\/j.ijgc.2024.100005_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0014389","article-title":"Aromatase is a direct target of FOXl2: C134W in granulosa cell tumors via a single highly conserved binding site in the ovarian specific promoter","volume":"5","author":"Fleming","year":"2010","journal-title":"PLoS One"},{"issue":"26","key":"10.1016\/j.ijgc.2024.100005_bib13","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1056\/NEJMoa0902542","article-title":"Mutation of FOXL2 in granulosa-cell tumors of the ovary","volume":"360","author":"Shah","year":"2009","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ijgc.2024.100005_bib14","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ygyno.2021.07.024","article-title":"A phase 2 study of anastrozole in patients with oestrogen receptor and\/progesterone receptor positive recurrent\/metastatic granulosa cell tumours\/sex-cord stromal tumours of the ovary: the Paragon\/ANZGOG 0903 trial","volume":"163","author":"Banerjee","year":"2021","journal-title":"Gynecol Oncol"},{"issue":"10","key":"10.1016\/j.ijgc.2024.100005_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0204973","article-title":"Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers","volume":"13","author":"Cottu","year":"2018","journal-title":"PLoS One"},{"issue":"1-2","key":"10.1016\/j.ijgc.2024.100005_bib16","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jsbmb.2008.11.015","article-title":"Global gene expression profiling of progesterone receptor modulators in T47D cells provides a new classification system","volume":"113","author":"Afh\u00fcppe","year":"2009","journal-title":"J Steroid Biochem Mol Biol."},{"issue":"2","key":"10.1016\/j.ijgc.2024.100005_bib17","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1074\/jbc.271.2.1209","article-title":"Two types of anti-progestins have distinct effects on site-specific phosphorylation of human progesterone receptor","volume":"271","author":"Beck","year":"1996","journal-title":"J Biol Chem"},{"issue":"suppl 16","key":"10.1016\/j.ijgc.2024.100005_bib18","article-title":"OATH trial: a phase II clinical trial evaluating the combination of onapristone with anastrozole for women with hormone receptor positive endometrial cancer\u2014preliminary results","volume":"41","author":"Schilder","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijgc.2024.100005_bib19","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ygyno.2024.06.026","article-title":"Basket study of oral progesterone antagonist onapristone extended release in progesterone receptor-positive recurrent granulosa cell, low-grade serous ovarian cancer, or endometrioid endometrial cancer","volume":"189","author":"Andres","year":"2024","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijgc.2024.100005_bib20","unstructured":"BOND Ready-to-Use Primary Antibody Progesterone Receptor (16). Leica Biosystems. Accessed December 17, 2024. https:\/\/shop.leicabiosystems.com\/us\/actions\/ViewProductAttachment-OpenFile?LocaleId=en_US&DirectoryPath=LBSAMS_IFUs&FileName=pa0436_us.pdf&UnitName=LBS#:\u223c:text=vitro%20diagnostic%20use.-,BOND%20Ready%2Dto%2DUse%20Primary%20Antibody%20Progesterone%20Receptor%20(16,MAX%20or%20BOND%2DIII%20systems."},{"issue":"2","key":"10.1016\/j.ijgc.2024.100005_bib21","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijgc.2024.100005_bib22","series-title":"Services, U.S. D.o.H.a.H., CTCAE. v5.0","year":"2017"},{"issue":"15","key":"10.1016\/j.ijgc.2024.100005_bib23","doi-asserted-by":"crossref","first-page":"4614","DOI":"10.1158\/1078-0432.CCR-06-0248","article-title":"High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients","volume":"12","author":"Stendahl","year":"2006","journal-title":"Clin Cancer Res."},{"issue":"3","key":"10.1016\/j.ijgc.2024.100005_bib24","first-page":"753","article-title":"Immunohistochemical significance of ER alpha, inhibin A, calretinin, and Ki67 expression in granulosa cell ovarian tumors","volume":"58","author":"Balan","year":"2017","journal-title":"Rom J Morphol Embryol."},{"issue":"suppl 1","key":"10.1016\/j.ijgc.2024.100005_bib25","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.ygyno.2023.06.466","article-title":"GOG 3026: a phase II trial of letrozole + ribociclib in women with recurrent low-grade serous carcinoma of the ovary, fallopian tube or peritoneum: a GOG Foundation study (001)","volume":"176","author":"Slomovitz","year":"2023","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1016\/j.ijgc.2024.100005_bib26","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000926","article-title":"Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers","volume":"5","author":"Colon-Otero","year":"2020","journal-title":"ESMO Open"},{"issue":"3","key":"10.1016\/j.ijgc.2024.100005_bib27","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/15384047.2019.1685291","article-title":"Durable response to palbociclib and letrozole in ovarian cancer with CDKN2A loss","volume":"21","author":"Frisone","year":"2020","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.ijgc.2024.100005_bib28","article-title":"Efficacy of cyclin-dependent kinase 4\/6 inhibitors in combination with hormonal therapy in patients with recurrent granulosa cell tumor of the ovary: a case series","volume":"50","author":"Albright","year":"2023","journal-title":"Gynecol Oncol Rep"},{"issue":"4","key":"10.1016\/j.ijgc.2024.100005_bib29","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1136\/ijgc-2023-005189","article-title":"A phase II, multicenter, open-label study of abemaciclib and letrozole in patients with estrogen receptor-positive rare ovarian cancer: ALEPRO trial","volume":"34","author":"Ottenbourgs","year":"2024","journal-title":"Int J Gynecol Cancer"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24000318?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24000318?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T02:06:54Z","timestamp":1767233214000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24000318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1048891X24000318"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2024.100005","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Basket study of oral progesterone antagonist onapristone extended-release in combination with anastrozole in progesterone receptor-positive recurrent adult-type granulosa cell tumor of the ovary","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2024.100005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Society of Gynaecological Oncology and the International Gynecologic Cancer Society. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100005"}}